GO:0060961 phospholipase D inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060961 phospholipase D inhibitor activity describes a molecular function in which a protein or small molecule binds to phospholipase D (PLD) and reduces or prevents its enzymatic activity.
• Phospholipase D enzymes hydrolyze phosphatidylcholine to generate phosphatidic acid, a lipid second messenger, so inhibitors of PLD activity directly modulate lipid signaling.
• The small-molecule inhibitor FIPI (5-fluoro-2-indolyl des-chlorohalopemide) is a widely used pharmacological tool that blocks PLD activity and downstream calcium signaling in breast cancer cells.
• Endogenous lipid inhibitors of mammalian PLD have been identified, showing that phospholipase D inhibitor activity is not limited to synthetic compounds.
• PLD activity and its inhibition influence diverse processes including Golgi retention of KIT in gastrointestinal stromal tumors, neutrophil degranulation, and neuronal depolarization responses.
• Studying GO:0060961 requires combining biochemical PLD activity assays, lipidomics, CRISPR-based gene editing, and cell signaling readouts to establish causal roles.
Description
Phospholipase D (PLD) enzymes catalyze the hydrolysis of phosphatidylcholine to produce phosphatidic acid (PA), a critical lipid second messenger involved in vesicle trafficking, cell proliferation, and immune signaling. Because dysregulated PLD activity contributes to cancer progression, metabolic disorders, and immune dysfunction, mechanisms that restrain PLD activity are of major therapeutic interest. GO:0060961, phospholipase D inhibitor activity, captures the molecular function of factors that bind to PLD and stop, prevent, or reduce its catalytic activity. This term is distinct from generic enzyme regulator activity because it specifically describes inhibition of phospholipase D, a defined enzyme class with well-characterized roles in signaling and membrane dynamics. Researchers studying lipid signaling, membrane trafficking, and oncology need to understand this activity to design experiments that distinguish direct PLD inhibition from indirect effects on downstream pathways. The availability of pharmacological inhibitors such as FIPI and the identification of endogenous lipid inhibitors have made GO:0060961 a tractable target for mechanistic and translational studies. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of phospholipase D inhibitor activity, its regulatory context, disease relevance, and experimental approaches for functional validation.
phospholipase D inhibitor activity At A Glance
| GO ID | GO:0060961 |
|---|---|
| GO term | phospholipase D inhibitor activity |
| Ontology | molecular_function |
| Synonym | none listed in QuickGO |
| Major function | Binds to and reduces or prevents the enzymatic activity of phospholipase D enzymes |
| Target enzyme | Phospholipase D (PLD), including PLD1 and PLD2 isoforms |
| Representative inhibitor | FIPI (5-fluoro-2-indolyl des-chlorohalopemide), a small-molecule PLD inhibitor |
| Endogenous examples | Lipid inhibitors of mammalian PLD have been biochemically identified |
| Related disease areas | Cancer, immune regulation, metabolic signaling, and gastrointestinal stromal tumors |
What Is GO:0060961?
GO:0060961 phospholipase D inhibitor activity is a molecular function defined by the Gene Ontology as binding to and stopping, preventing, or reducing the activity of phospholipase D. In practical terms, a gene product or chemical entity annotated with this activity interacts with one or more PLD enzymes (for example PLD1 or PLD2) and decreases their ability to hydrolyze phosphatidylcholine into phosphatidic acid and choline. This function can be exerted by proteins, peptides, or small molecules that directly associate with PLD and interfere with its catalytic mechanism, substrate access, or regulatory cofactor binding. The term is therefore narrower than general enzyme inhibitor activity because it is restricted to phospholipase D as the target enzyme.
Why Is phospholipase D inhibitor activity Important in Cell Biology?
Phospholipase D inhibitor activity is important because PLD enzymes sit at the crossroads of lipid signaling, membrane trafficking, and cell proliferation, and their dysregulation is implicated in cancer, immune disorders, and metabolic disease. Pharmacological inhibition of PLD with compounds such as FIPI blocks EGF-induced calcium signaling in human breast cancer cells, demonstrating that reducing PLD activity can interrupt oncogenic signaling cascades. In gastrointestinal stromal tumors, PLD activity is required for Golgi retention of the KIT receptor, linking PLD inhibition to altered receptor localization and potentially to therapeutic strategies. Endogenous inhibitors of PLD have been identified in mammalian systems, suggesting that phospholipase D inhibitor activity is a physiologically relevant regulatory mechanism rather than only a pharmacological concept. Understanding GO:0060961 therefore supports both basic research into lipid signaling and translational efforts to target PLD in disease.
• Provides a molecular mechanism to dampen phosphatidic acid production and downstream lipid signaling.
• Pharmacological PLD inhibition with FIPI blocks EGF-induced calcium signaling in breast cancer cells, highlighting anti-tumor potential.
• PLD activity is required for Golgi retention of KIT in gastrointestinal stromal tumor cells, so inhibitors may alter receptor trafficking.
• Endogenous lipid inhibitors of mammalian PLD exist, indicating physiological regulation of PLD activity.
• PLD inhibition can modulate neutrophil degranulation, linking the activity to innate immune responses.
• Neuronal PLD activity is modulated under depolarizing conditions, suggesting roles in synaptic and neuronal signaling.
• PLD enzymes are emerging therapeutic targets in signaling, metabolism, and immuno-oncology, making inhibitor activity highly relevant.
• Structural insights into PLD enzymes support rational design of inhibitors annotated with GO:0060961.
• In vitro modulation of PLD activity provides assays to quantify inhibitor potency and mechanism.
• CRISPR-based editing of PLD genes or inhibitor candidates enables causal testing of GO:0060961 in disease models.
What Happens During phospholipase D inhibitor activity?
Recognition and binding to phospholipase D
In simple terms: An inhibitor first has to find and stick to the phospholipase D enzyme.
The initial step of phospholipase D inhibitor activity is the physical association between the inhibitor and the PLD enzyme. Small-molecule inhibitors such as FIPI are thought to occupy the enzyme active site or an allosteric pocket, thereby preventing substrate access or catalysis. Endogenous lipid inhibitors of mammalian PLD have been identified biochemically, indicating that natural molecules can also bind and reduce PLD activity. Structural studies of PLD enzymes provide a framework for understanding how inhibitors dock into conserved domains and interfere with catalytic residues.
Suppression of phosphatidylcholine hydrolysis
In simple terms: Once bound, the inhibitor stops PLD from cutting phosphatidylcholine into phosphatidic acid.
PLD normally hydrolyzes phosphatidylcholine to generate phosphatidic acid and choline, and this reaction is central to lipid signaling. When an inhibitor engages PLD, the hydrolysis of phosphatidylcholine is reduced, leading to lower phosphatidic acid levels. In vitro modulation studies have characterized how reaction conditions and inhibitors affect PLD catalytic output, providing quantitative readouts for this suppression. The reduction in phosphatidic acid production is the key biochemical consequence of GO:0060961 activity.
Downstream signaling consequences
In simple terms: Blocking PLD changes the signals that the cell sends, especially calcium and growth signals.
Phosphatidic acid produced by PLD participates in multiple signaling pathways, including calcium mobilization and growth factor responses. The PLD inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells, showing that inhibition of PLD activity can interrupt receptor-driven calcium flux. In gastrointestinal stromal tumor cells, PLD activity is required for Golgi retention of KIT, so inhibition may alter receptor localization and downstream signaling. These examples illustrate how GO:0060961 activity propagates from lipid metabolism to cell biological outcomes.
Physiological and pharmacological contexts
In simple terms: Inhibitors of PLD can be natural molecules in the body or drugs used in experiments.
Endogenous lipid inhibitors of mammalian PLD have been identified, suggesting that phospholipase D inhibitor activity operates in physiological settings. Pharmacologically, compounds such as FIPI are used to probe PLD function in cells and animal models. Diethylstilbestrol inhibits PLD activity and degranulation in stimulated human neutrophils, indicating that certain drugs can also exert this activity. Neuronal PLD activity is modulated under depolarizing conditions, further supporting context-dependent regulation of PLD and its inhibitors.
Key Genes Involved in GO:0060961 phospholipase D inhibitor activity
The following genes and proteins are central to phospholipase D inhibitor activity, either as the target enzymes (PLD isoforms), as pharmacological or endogenous inhibitors, or as downstream effectors that report on PLD inhibition.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLD1 | Phospholipase D isoform that hydrolyzes phosphatidylcholine to phosphatidic acid; target of inhibitors | Key target for GO:0060961; knockout and point-mutation models reveal isoform-specific functions |
| PLD2 | Phospholipase D isoform with roles in membrane signaling; target of inhibitors | Studied alongside PLD1 to dissect redundant and distinct inhibitor-sensitive pathways |
| KIT | Receptor tyrosine kinase whose Golgi retention depends on PLD activity in GIST cells | Readout for PLD inhibition; knock-in and tagged models can track KIT localization |
| EGFR | Growth factor receptor upstream of PLD-dependent calcium signaling | Used in FIPI studies to test whether PLD inhibition blocks EGF-induced calcium flux |
| FIPI (tool compound) | Small-molecule PLD inhibitor that blocks EGF-induced calcium signaling | Pharmacological probe for GO:0060961; used in breast cancer cell models |
| Endogenous lipid inhibitor (unnamed) | Biochemically identified lipid that inhibits mammalian PLD | Provides evidence for natural phospholipase D inhibitor activity |
| Diethylstilbestrol | Drug that inhibits PLD activity and neutrophil degranulation | Links GO:0060961 to immune cell function and drug repurposing |
| PLD enzyme (neuronal context) | PLD activity modulated under depolarizing conditions | Supports studies of PLD inhibitors in neuronal signaling |
| PLD structural domains | Catalytic and regulatory domains targeted by inhibitors | Guide rational design of new inhibitors annotated with GO:0060961 |
| Phosphatidic acid (lipid product) | Product of PLD activity; reduced when inhibitors act | Lipidomic readout for PLD inhibitor activity |
| Choline (product) | Byproduct of PLD-mediated phosphatidylcholine hydrolysis | Can be measured to quantify PLD inhibition |
| Calcium signaling machinery | Downstream effector of PLD-derived phosphatidic acid | Functional readout in FIPI-treated breast cancer cells |
| Neutrophil degranulation machinery | Process inhibited when PLD activity is reduced | Immune cell model for GO:0060961 |
| Golgi trafficking machinery | Mediates KIT retention in GIST cells in a PLD-dependent manner | Cell biology readout for PLD inhibition |
| PLD1/PLD2 double-knockout models | Genetic ablation of PLD activity | Compare genetic vs pharmacological inhibition of GO:0060961 |
| PLD inhibitor binding pocket residues | Structural determinants of inhibitor sensitivity | Point-mutation models to test inhibitor binding |
How Is phospholipase D inhibitor activity Regulated?
Phospholipase D inhibitor activity is regulated at multiple levels. Pharmacological inhibitors such as FIPI can be applied exogenously to acutely block PLD activity, and their effects are dose- and context-dependent. Endogenous lipid inhibitors of mammalian PLD have been identified, suggesting that intracellular lipid composition can regulate PLD activity. In neurons, PLD activity is modulated under depolarizing conditions, indicating that physiological stimuli can alter the balance between PLD activity and its inhibition. In immune cells, diethylstilbestrol inhibits PLD activity and degranulation, showing that hormonal or pharmacological signals can regulate this activity. Structural insights into PLD enzymes further suggest that inhibitor binding can be influenced by the conformational state of the enzyme and its membrane environment. Together, these findings indicate that phospholipase D inhibitor activity is not constitutive but is dynamically controlled by cellular context, lipid environment, and exogenous compounds.
phospholipase D inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLD1 | Cancer and oncogenic signaling | PLD1 knockout cancer cell lines with FIPI treatment |
| PLD2 | Cancer and membrane signaling | PLD2 point-mutation models to test inhibitor sensitivity |
| KIT | Gastrointestinal stromal tumor | GIST cell lines with PLD inhibition and KIT trafficking assays |
| EGFR | Breast cancer calcium signaling | Breast cancer cells treated with FIPI and EGF |
| Neutrophil PLD | Immune degranulation | Primary neutrophils treated with diethylstilbestrol |
Cancer and oncogenic signaling
Phospholipase D activity contributes to cancer cell proliferation and survival, and its inhibition is being explored as an anti-tumor strategy. The PLD inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells, demonstrating that GO:0060961 activity can interrupt a key oncogenic pathway. In gastrointestinal stromal tumors, PLD activity is required for Golgi retention of the KIT receptor, a driver oncogene, suggesting that PLD inhibitors could alter KIT localization and signaling. These findings position phospholipase D inhibitor activity as a potential therapeutic mechanism in cancers dependent on PLD and receptor tyrosine kinase signaling.
Immune regulation and inflammation
PLD activity is involved in immune cell functions such as neutrophil degranulation, and its inhibition can dampen these responses. Diethylstilbestrol inhibits PLD activity and degranulation in stimulated human neutrophils, linking GO:0060961 to modulation of innate immunity. Because PLD-derived phosphatidic acid participates in inflammatory signaling, inhibitors may have utility in inflammatory or autoimmune contexts. However, the precise therapeutic window and cell-type specificity of PLD inhibition remain areas of active investigation.
Neurological and signaling disorders
Neuronal PLD activity is modulated under depolarizing conditions, suggesting roles in synaptic signaling and neuronal excitability. Inhibitors of PLD could therefore influence neuronal responses, although direct evidence for therapeutic benefit in neurological disease is still limited. Structural and biochemical studies of PLD enzymes provide a foundation for developing brain-penetrant inhibitors to test in neuronal models. Further research is needed to determine whether phospholipase D inhibitor activity can be harnessed for neurological indications.
From phospholipase D inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLD1 reduce phosphatidic acid production? | PLD1 knockout cell line |
| Does a point mutation in the PLD active site confer inhibitor resistance? | PLD1/PLD2 point-mutation knock-in |
| Can a tagged PLD allele report inhibitor binding in live cells? | Tagged knock-in of PLD1 or PLD2 |
| Does overexpression of PLD enhance EGF-induced calcium signaling? | PLD overexpression in breast cancer cells |
| Does PLD inhibition alter KIT Golgi retention? | GIST cells with PLD inhibitor treatment |
| Does PLD inhibition block neutrophil degranulation? | Primary neutrophils with diethylstilbestrol |
How to Study the phospholipase D inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| PLD activity assay | Enzymatic production of phosphatidic acid or choline | Testing inhibitor potency in vitro |
| Lipidomics (mass spectrometry) | Changes in phosphatidic acid and related lipids | Global lipid signaling after PLD inhibition |
| Calcium imaging | Intracellular calcium flux | FIPI effects on EGF-induced signaling |
| CRISPR knockout | Loss of PLD gene function | Causal testing of PLD isoforms |
| Point-mutation knock-in | Inhibitor binding site integrity | Testing resistance to PLD inhibitors |
| Tagged knock-in | Protein localization and trafficking | Tracking KIT Golgi retention |
| Overexpression | Gain of PLD signaling | Enhancing EGF-induced calcium responses |
| Neutrophil degranulation assay | Immune cell granule release | Testing diethylstilbestrol effects |
Biochemical PLD activity assays
Measuring phospholipase D inhibitor activity requires direct assays of PLD enzymatic function, typically using radiolabeled or fluorescent phosphatidylcholine substrates to quantify phosphatidic acid or choline production. In vitro modulation studies have established conditions for testing inhibitors and comparing their potency. These assays are essential for confirming that a candidate gene product or compound directly inhibits PLD rather than acting indirectly.
Lipidomics and phosphatidic acid quantification
Because PLD inhibition reduces phosphatidic acid levels, lipidomic profiling by mass spectrometry can quantify changes in PA and related lipids after inhibitor treatment or genetic manipulation. This approach provides a global view of lipid signaling rewiring and can identify compensatory pathways. Lipidomics is particularly useful when combined with genetic models to establish causality for GO:0060961.
Cell signaling and calcium imaging
Functional consequences of PLD inhibition can be monitored using calcium imaging, as FIPI blocks EGF-induced calcium signaling in breast cancer cells. Live-cell imaging of calcium indicators allows real-time assessment of inhibitor effects on receptor-driven signaling. These readouts connect molecular inhibition to physiological responses.
CRISPR-based genetic validation
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of genes involved in phospholipase D inhibitor activity. For example, PLD1 or PLD2 knockout cells can be used to determine whether inhibitor effects require the target enzyme. Point mutations in the PLD active site can test whether inhibitor binding depends on specific residues. Tagged knock-in alleles allow tracking of PLD localization and inhibitor-induced changes.
How CRISPR Can Be Used to Study GO:0060961 phospholipase D inhibitor activity
Knockout
CRISPR knockout of PLD1 or PLD2 can eliminate target enzyme expression, allowing researchers to test whether phospholipase D inhibitor activity depends on these isoforms. Knockout models are useful for distinguishing direct inhibition from off-target effects of pharmacological inhibitors such as FIPI. In cancer cell lines, PLD knockout can be combined with EGF stimulation and calcium imaging to assess signaling outcomes.
Point Mutation
Point mutations in the PLD catalytic domain can be introduced to test whether specific residues are required for inhibitor binding or enzyme activity. Structural insights into PLD enzymes guide the selection of residues to mutate. These models help validate whether a candidate inhibitor acts through the expected binding pocket.
Knock-in
Knock-in of tagged PLD alleles enables live-cell tracking of enzyme localization and inhibitor-induced changes. For example, tagging KIT or PLD can reveal how PLD inhibition alters Golgi retention in GIST cells. Knock-in models also allow expression of inhibitor-resistant PLD variants to dissect downstream pathways.
Overexpression
Overexpression of PLD1 or PLD2 can amplify phosphatidic acid signaling and sensitize cells to inhibitors. In breast cancer cells, PLD overexpression may enhance EGF-induced calcium signaling, providing a gain-of-function platform for testing GO:0060961. Overexpression models are also useful for biochemical purification of PLD for inhibitor studies.
How EDITGENE Supports phospholipase D inhibitor activity Research
Researchers studying phospholipase D inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in PLD inhibition or downstream signaling, and CRISPR-based models provide the most direct way to establish such causality. By combining knockout, point-mutation, knock-in, and overexpression strategies, it is possible to dissect the molecular determinants of GO:0060961 and its disease relevance.
Contact EDITGENE today to design your custom CRISPR model for phospholipase D inhibitor activity research.
Frequently Asked Questions About phospholipase D inhibitor activity
What is phospholipase D inhibitor activity?
GO:0060961 phospholipase D inhibitor activity is a molecular function in which a factor binds to phospholipase D and stops, prevents, or reduces its enzymatic activity.
What genes are involved in phospholipase D inhibitor activity?
The main target genes are PLD1 and PLD2, which encode phospholipase D isoforms; downstream readouts include KIT and EGFR signaling components.
What is the GO ID for phospholipase D inhibitor activity?
The Gene Ontology ID is GO:0060961, under the molecular_function aspect.
How does FIPI inhibit phospholipase D?
FIPI is a small-molecule PLD inhibitor that blocks EGF-induced calcium signaling in human breast cancer cells, likely by occupying the PLD active site or an allosteric pocket.
Are there natural inhibitors of phospholipase D?
Yes, endogenous lipid inhibitors of mammalian phospholipase D have been biochemically identified.
What diseases are linked to phospholipase D inhibitor activity?
PLD inhibition is studied in cancer, gastrointestinal stromal tumors, immune regulation, and neuronal signaling.
How can I study phospholipase D inhibitor activity in the lab?
Common methods include PLD activity assays, lipidomics, calcium imaging, and CRISPR-based knockout or knock-in models.
Does phospholipase D inhibition affect KIT localization?
Yes, PLD activity is required for Golgi retention of KIT in gastrointestinal stromal tumor cells, so inhibition can alter KIT trafficking.
Can CRISPR be used to validate phospholipase D inhibitor targets?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of PLD isoforms and inhibitor binding sites.
What is the role of phospholipase D in neutrophils?
PLD activity contributes to neutrophil degranulation, and diethylstilbestrol inhibits both PLD activity and degranulation in stimulated human neutrophils.
Conclusion
GO:0060961 phospholipase D inhibitor activity defines a molecular function that restrains phospholipase D enzymes and their production of phosphatidic acid, a central lipid second messenger. Pharmacological inhibitors such as FIPI and endogenous lipid inhibitors demonstrate that this activity can be exerted by diverse molecules and has measurable effects on calcium signaling, receptor trafficking, and immune cell function. Understanding the mechanisms, genes, and disease contexts of phospholipase D inhibitor activity supports both basic research and therapeutic development. CRISPR-based models, combined with biochemical and lipidomic assays, provide a robust toolkit for dissecting this activity and its roles in cancer, immunity, and neuronal signaling.
References
- 1. Stricker HM et al.. 2021. The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells.. Cell Commun Signal 19(1):43 PMID: 33832505
- 2. Obata Y et al.. 2025. Golgi retention of KIT in gastrointestinal stromal tumour cells is phospholipase D activity-dependent.. Sci Rep 15(1):28778 PMID: 40770227
- 3. Tang L et al.. 2025. Phospholipase D: emerging therapeutic targets in signaling, metabolism, and immune-oncology.. Cell Commun Signal 24(1):42 PMID: 41420235
- 4. Tou JS et al.. 2008. Diethylstilbestrol inhibits phospholipase D activity and degranulation by stimulated human neutrophils.. Steroids 73(2):216-21 PMID: 18036628
- 5. Waring M et al.. 1999. Modulation of neuronal phospholipase D activity under depolarizing conditions.. FEBS Lett 464(1-2):21-4 PMID: 10611476
- 6. Kawabe K et al.. 1998. Identification of lipid inhibitor of mammalian phospholipase D.. J Biochem 123(5):870-5 PMID: 9562619
- 7. Mansfeld J et al.. 2009. Modulation of phospholipase D activity in vitro.. Biochim Biophys Acta 1791(9):913-26 PMID: 19286472
- 8. Stieglitz KA. 2018. Structural Insights for Drugs Developed for Phospholipase D Enzymes.. Curr Drug Discov Technol 15(2):81-93 PMID: 28814238
